Holen Sie sich die Stockscreener-App
294.46
0.57%
-1.6546
Schlusskurs vom Vortag:
$296.11
Offen:
$298
24-Stunden-Volumen:
625.49K
Relative Volume:
0.50
Marktkapitalisierung:
$39.29B
Einnahmen:
$3.71B
Nettoeinkommen (Verlust:
$313.75M
KGV:
130.46
EPS:
2.2571
Netto-Cashflow:
$465.38M
1W Leistung:
-4.56%
1M Leistung:
-7.66%
6M Leistung:
-30.47%
1J Leistung:
+13.51%
1-Tages-Spanne:
$288.06
$300.49
1-Wochen-Bereich:
$287.00
$317.56
52-Wochen-Spanne:
$245.96
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
294.43 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.88 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.60 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
295.45 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - Business Wire
Alnylam Pharmaceuticals Q1 2026 earnings preview - MSN
Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Danske Bank A S - MarketBeat
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $500 - Moomoo
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam Pharma (ALNY) Gets a Buy from Bernstein - The Globe and Mail
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Wall Street Zen - MarketBeat
Alnylam slips 4.3% as investors digest Q1 results and unchanged full-year outlook - Quiver Quantitative
ALNY Maintained by RBC Capital -- Price Target Lowered to $445 - GuruFocus
ALNY Maintained by Wells Fargo -- Price Target Raised to $377 - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year - Seeking Alpha
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Yahoo Finance
Bernstein SocGen lowers Alnylam stock price target on valuation By Investing.com - Investing.com Canada
Bernstein SocGen lowers Alnylam stock price target on valuation - Investing.com
Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $377 to $527 - Moomoo
RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating - marketscreener.com
Alnylam Pharmaceuticals Backs 2026 Views >ALNY - Moomoo
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Jennison Associates LLC - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals (ALNY) Earnings Turn To Profitability Challenges Premium P/E Narrative - simplywall.st
Congress Large Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
ALNY SWOT Analysis: Strong Growth Potential Revealed in 10-Q Fil - GuruFocus
Alnylam Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) 2026-04-30 - Seeking Alpha
Alnylam Pharmaceuticals Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
Alnylam Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Alnylam Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Alnylam (ALNY) Reports Impressive Q1 Revenue Growth - GuruFocus
Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2026 Earnings a - GuruFocus
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Alnylam Pharmaceuticals Q1 2026 Earnings: AMVUTTRA Drives 153% TTR Revenue Growth and Pipeline Advances in RNAi Therapeutics 101551 - Minichart
Alnylam Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Alnylam Q1 2026 slides: historic $1B revenue milestone on ATTR-CM surge - Investing.com India
Earnings call transcript: Alnylam Q1 2026 sees record revenue, EPS beat - Investing.com Canada
Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Is Alnylam Pharmaceuticals (ALNY) Still 41.3% Undervalued After - GuruFocus
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
[10-Q] ALNYLAM PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Pfizer deals extend patent life for a top-selling rare disease drug - Pharma Voice
Q1 2026 Alnylam Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Alnylam Reports Q1 2026: $1.17B Total Revenue, $1.036B Net Product Revenue, $206M Net Income - TradingView
Alnylam: Q1 Earnings Snapshot - KHOU
(ALNY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Press Release: Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress - Moomoo
H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY) - The Globe and Mail
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
0.15%
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):